RS60773B1 - Stabilna anti-ifnar1 formulacija - Google Patents

Stabilna anti-ifnar1 formulacija

Info

Publication number
RS60773B1
RS60773B1 RS20201103A RSP20201103A RS60773B1 RS 60773 B1 RS60773 B1 RS 60773B1 RS 20201103 A RS20201103 A RS 20201103A RS P20201103 A RSP20201103 A RS P20201103A RS 60773 B1 RS60773 B1 RS 60773B1
Authority
RS
Serbia
Prior art keywords
ifnar1
formulation
stable anti
stable
ifnar1 formulation
Prior art date
Application number
RS20201103A
Other languages
English (en)
Inventor
Roberto Depaz
Natalie Dejesus
Jared Bee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58052002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS60773(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of RS60773B1 publication Critical patent/RS60773B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
RS20201103A 2015-08-19 2016-08-18 Stabilna anti-ifnar1 formulacija RS60773B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562207164P 2015-08-19 2015-08-19
PCT/US2016/047506 WO2017031288A1 (en) 2015-08-19 2016-08-18 Stable anti-ifnar1 formulation
EP16837818.0A EP3337502B1 (en) 2015-08-19 2016-08-18 Stable anti-ifnar1 formulation

Publications (1)

Publication Number Publication Date
RS60773B1 true RS60773B1 (sr) 2020-10-30

Family

ID=58052002

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20201103A RS60773B1 (sr) 2015-08-19 2016-08-18 Stabilna anti-ifnar1 formulacija
RS20230447A RS64263B1 (sr) 2015-08-19 2016-08-18 Stabilna anti-ifnar1 formulacija

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20230447A RS64263B1 (sr) 2015-08-19 2016-08-18 Stabilna anti-ifnar1 formulacija

Country Status (24)

Country Link
US (1) US10125195B2 (sr)
EP (3) EP3769781B1 (sr)
JP (3) JP6720293B2 (sr)
KR (4) KR102168005B1 (sr)
CN (1) CN107921109A (sr)
AU (3) AU2016308262C1 (sr)
BR (1) BR112018002196A8 (sr)
CA (1) CA2995222C (sr)
CY (2) CY1123657T1 (sr)
DK (2) DK3769781T5 (sr)
ES (2) ES2818229T3 (sr)
FI (1) FI3769781T3 (sr)
HK (1) HK1256195A1 (sr)
HR (2) HRP20230463T1 (sr)
HU (2) HUE051862T2 (sr)
IL (1) IL257279B2 (sr)
LT (2) LT3769781T (sr)
PL (2) PL3769781T3 (sr)
PT (2) PT3337502T (sr)
RS (2) RS60773B1 (sr)
RU (1) RU2731737C2 (sr)
SG (1) SG10202106970XA (sr)
SI (2) SI3337502T1 (sr)
WO (1) WO2017031288A1 (sr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3337502T1 (sl) 2015-08-19 2020-10-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20200061015A1 (en) * 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
CN113474360A (zh) 2019-02-18 2021-10-01 伊莱利利公司 治疗性抗体制剂
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
IL292706A (en) * 2019-11-11 2022-07-01 Astrazeneca Ab Inhibition of type i interferon in systemic lupus erythematosus
EP4157873A2 (en) 2020-05-29 2023-04-05 Astrazeneca AB Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
CA3187785A1 (en) 2020-06-25 2021-12-30 Medimmune Limited Prevention of axonal damage using antibody binding to amyloid beta 1-42
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
CN117157099A (zh) * 2021-04-23 2023-12-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
JP7484027B2 (ja) 2021-04-23 2024-05-15 アストラゼネカ・アクチエボラーグ 皮下注射のための抗ｉｆｎａｒ１投薬計画
KR20240000557A (ko) 2021-04-23 2024-01-02 아스트라제네카 아베 피부 홍반 루푸스의 치료
WO2022223771A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
IL308128A (en) 2021-05-12 2023-12-01 Astrazeneca Ab Inhibitor of type 1 interferon receptor spares steroids in patients with systemic lupus erythematosus
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂
CN113527490B (zh) * 2021-07-13 2022-03-01 江苏荃信生物医药股份有限公司 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
EP4377349A1 (en) 2021-07-27 2024-06-05 Astrazeneca AB Treatment of lupus
AU2022359684A1 (en) 2021-10-04 2024-05-09 Astrazeneca Ab Treatment of lupus
CA3234358A1 (en) * 2021-10-29 2023-05-04 Intas Pharmaceuticals Ltd. Stable lyophilized formulation of an anti-.alpha.4.beta.7 antibody
WO2023155902A1 (en) * 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
WO2024009205A1 (en) * 2022-07-06 2024-01-11 Intas Pharmaceuticals Ltd. STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY
WO2024079241A1 (en) 2022-10-13 2024-04-18 Astrazeneca Ab Treatment of lupus

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
PL1781705T3 (pl) 2004-06-21 2015-03-31 Squibb & Sons Llc Antyciała receptora interferonów alfa I oraz ich zastosowania
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
CA2713981C (en) 2008-02-08 2016-11-01 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
BRPI0921845A2 (pt) * 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
KR20140103099A (ko) * 2011-10-12 2014-08-25 아센디스 파마 옵탈몰로지 디비젼 에이/에스 안구 병태의 예방 및 치료
EP2771033A4 (en) * 2011-10-28 2016-02-17 Integritybio Inc PROTEIN FORMULATIONS CONTAINING AMINO ACIDS
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
BR112015008186A2 (pt) 2012-10-25 2017-09-19 Medimmune Llc formulação de um anticorpo estável e de baixa viscosidade
CA2910065C (en) * 2013-05-15 2023-09-19 Medimmune Limited Purification of recombinantly produced polypeptides
RU2675824C2 (ru) * 2013-09-11 2018-12-25 Игл Байолоджикс, Инк. Жидкие белковые составы, содержащие ионные жидкости
EP3062814A1 (en) 2013-10-29 2016-09-07 Albumedix A/S Antibody composition
EP3188757A1 (en) 2014-09-03 2017-07-12 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
WO2016109822A1 (en) 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
SI3337502T1 (sl) 2015-08-19 2020-10-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1

Also Published As

Publication number Publication date
LT3337502T (lt) 2020-09-25
ES2947488T3 (es) 2023-08-10
FI3769781T3 (fi) 2023-06-07
ES2818229T3 (es) 2021-04-09
DK3337502T3 (da) 2020-09-14
HUE061985T2 (hu) 2023-09-28
PT3337502T (pt) 2020-09-23
RU2018107725A3 (sr) 2019-10-02
PL3769781T3 (pl) 2023-07-17
AU2020203306A1 (en) 2020-06-11
JP7035119B2 (ja) 2022-03-14
US20170051066A1 (en) 2017-02-23
HRP20230463T1 (hr) 2023-07-21
IL257279B (en) 2022-12-01
JP2022066345A (ja) 2022-04-28
EP3769781B1 (en) 2023-04-19
AU2016308262B2 (en) 2020-04-30
IL257279B2 (en) 2023-04-01
PL3337502T3 (pl) 2021-01-11
JP6720293B2 (ja) 2020-07-08
SI3769781T1 (sl) 2023-06-30
KR20200119916A (ko) 2020-10-20
AU2016308262C1 (en) 2022-04-21
AU2016308262A1 (en) 2018-03-08
IL257279A (en) 2018-03-29
RS64263B1 (sr) 2023-07-31
SI3337502T1 (sl) 2020-10-30
AU2020203306C1 (en) 2022-03-31
BR112018002196A2 (pt) 2019-04-30
DK3769781T3 (da) 2023-06-19
CY1126062T1 (el) 2023-11-15
SG10202106970XA (en) 2021-07-29
EP4233892A2 (en) 2023-08-30
EP3337502B1 (en) 2020-06-24
KR20180041173A (ko) 2018-04-23
EP3337502A4 (en) 2019-01-23
CN107921109A (zh) 2018-04-17
JP2018523676A (ja) 2018-08-23
AU2020203306B2 (en) 2021-09-09
RU2018107725A (ru) 2019-09-19
KR102168005B1 (ko) 2020-10-21
HK1256195A1 (zh) 2019-09-13
RU2731737C2 (ru) 2020-09-08
CY1123657T1 (el) 2022-03-24
US10125195B2 (en) 2018-11-13
EP3337502A1 (en) 2018-06-27
EP4233892A3 (en) 2023-10-25
CA2995222C (en) 2021-07-13
CA2995222A1 (en) 2017-02-23
BR112018002196A8 (pt) 2021-05-04
KR20240090616A (ko) 2024-06-21
EP3769781A1 (en) 2021-01-27
DK3769781T5 (da) 2024-08-19
KR102669174B1 (ko) 2024-06-10
HUE051862T2 (hu) 2021-03-29
KR20220127378A (ko) 2022-09-19
PT3769781T (pt) 2023-06-19
HRP20201297T1 (hr) 2020-11-27
WO2017031288A1 (en) 2017-02-23
AU2021257915A1 (en) 2021-11-18
JP2020158527A (ja) 2020-10-01
LT3769781T (lt) 2023-06-12

Similar Documents

Publication Publication Date Title
HK1256195A1 (zh) 穩定的抗ifnar1配製品
GB201513010D0 (en) Novel formulation
GB201407934D0 (en) Formulation
GB201514758D0 (en) Formulation
GB201608356D0 (en) Formulation
SI3173071T1 (sl) Formulacija maropitanta
IL248835A0 (en) A preparation of ciritinib
GB201407384D0 (en) Formulation
IL251362A0 (en) formulation
GB201521771D0 (en) Formulation
GB201511255D0 (en) Formulation
GB201509891D0 (en) Formulation
GB201511301D0 (en) Formulation
GB201707615D0 (en) Formulation
PL3559185T3 (pl) Preparat nabłyszczający
GB201609925D0 (en) Formulation
GB201514014D0 (en) Formulation
GB201602048D0 (en) Formulation
GB201504662D0 (en) Formulation
GB201508527D0 (en) Novel formulation
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
GB201412754D0 (en) Formulation